Baby

Carter’s, Inc. Announces Participation at the BofA Securities 2024 Consumer and Retail Conference

Retrieved on: 
Friday, March 8, 2024

Carter’s, Inc. (NYSE:CRI), the largest branded marketer in North America of apparel exclusively for babies and young children, announced today that the Company will participate in a fireside chat at the BofA Securities 2024 Consumer and Retail Conference in Miami on Wednesday, March 13, 2024, at 8:00am Eastern Daylight Time.

Key Points: 
  • Carter’s, Inc. (NYSE:CRI), the largest branded marketer in North America of apparel exclusively for babies and young children, announced today that the Company will participate in a fireside chat at the BofA Securities 2024 Consumer and Retail Conference in Miami on Wednesday, March 13, 2024, at 8:00am Eastern Daylight Time.
  • A live webcast of the fireside chat will be available on the Investor Relations section of the Company’s website at ir.carters.com.

Hope for Women: Womed Unveils First Fertility Restoration Device Proven Effective in Randomized Clinical Trial

Retrieved on: 
Thursday, March 7, 2024

No device indicated for IUA prevention has been shown to be effective in this specific patient group.

Key Points: 
  • No device indicated for IUA prevention has been shown to be effective in this specific patient group.
  • PREG2 is an international, randomized clinical trial designed to measure Womed Leaf's effectiveness.
  • 160 women with severe or moderate IUA were randomly assigned to receive a Womed Leaf or not after adhesiolysis surgery.
  • "Womed Leaf, which is already registered in Europe and Brazil, will be marketed through commercial partners."

Masimo Celebrates Multiple Wins at the iF DESIGN AWARDS 2024

Retrieved on: 
Thursday, March 7, 2024

Masimo (NASDAQ: MASI) is proud to celebrate multiple wins across various categories at the prestigious iF DESIGN AWARDS 2024, showcasing its commitment to excellence in design and innovation throughout diverse industries.

Key Points: 
  • Masimo (NASDAQ: MASI) is proud to celebrate multiple wins across various categories at the prestigious iF DESIGN AWARDS 2024, showcasing its commitment to excellence in design and innovation throughout diverse industries.
  • The recognition from iF DESIGN AWARDS reaffirms Masimo's dedication to pushing the boundaries of design and technology to improve the lives of people around the world.
  • Joe Kiani, Founder and CEO of Masimo, said, “We are honored to be recognized by iF Design.
  • Masimo remains committed to advancing healthcare technologies and enhancing consumer experiences through cutting-edge design and innovation.

Owlet Announces Fourth Quarter and Fiscal Year 2023 Results

Retrieved on: 
Thursday, March 7, 2024

Owlet , Inc. (“Owlet” or the “Company”) (NYSE:OWLT), the pioneer of smart infant monitoring, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023.

Key Points: 
  • Owlet , Inc. (“Owlet” or the “Company”) (NYSE:OWLT), the pioneer of smart infant monitoring, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023.
  • I’m proud of the immense progress our team has made in re-shaping the Company in 2023, and I look forward to continued successes in 2024.”
    Financial Results for the Fourth Quarter and Fiscal Year Ended December 31, 2023
    Revenues for the fourth quarter of 2023 were approximately $21.0 million.
  • Adjusted EBITDA loss was approximately $0.7 million for the fourth quarter of 2023, compared to $15.2 million for the fourth quarter of 2022.
  • Net loss per share was $0.97 for the fourth quarter of 2023, compared to net loss per share of $2.43 for the fourth quarter of 2022.

Children’s Hospital Los Angeles Study Finds Many Kids With Sickle Cell Anemia Lack Preventative Care

Retrieved on: 
Wednesday, March 6, 2024

Children with sickle cell anemia are vulnerable to serious infections and stroke, but many do not receive the preventative care that could help them stay healthier for longer, a Children’s Hospital Los Angeles study found.

Key Points: 
  • Children with sickle cell anemia are vulnerable to serious infections and stroke, but many do not receive the preventative care that could help them stay healthier for longer, a Children’s Hospital Los Angeles study found.
  • The researchers measured how many young children with sickle cell anemia received adequate preventative antibiotics to prevent infection and if children and adolescents with sickle cell anemia received annual brain ultrasounds to assess their stroke risk.
  • “What we found, unfortunately, was not what we’d hoped for,” says Ashaunta Anderson , MD, MPH, MSHS, Pediatrician at Children’s Hospital Los Angeles , who led the study.
  • Twice-daily doses of antibiotics, given consistently, can protect young children with sickle cell anemia from developing serious infections.

QuidelOrtho Receives Health Canada Approval for Quidel® Triage® PLGF Test for Laboratory Use in Canada

Retrieved on: 
Wednesday, March 6, 2024

QuidelOrtho Corporation (Nasdaq:QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, has received approval from Health Canada for its Triage PLGF test for laboratory use in Canada.

Key Points: 
  • QuidelOrtho Corporation (Nasdaq:QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, has received approval from Health Canada for its Triage PLGF test for laboratory use in Canada.
  • The Triage PLGF test is a fluorescence immunoassay to be used with the small footprint Triage MeterPro® Instrument for the quantitative determination of placental growth factor (“PLGF”) in maternal plasma specimens.
  • With the Triage PLGF test, clinicians can be positioned to better detect angiogenic imbalance and assess the risk for these complications.
  • The Triage PLGF test is available to customers in Canada for use with the Triage MeterPro instrument.

Global Wearable Breast Pump Market Size, Share & Trends Analysis Report 2024: Now Available - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 6, 2024

The "Global Wearable Breast Pump Market Size, Share & Trends Analysis Report by Component (Wearable Pumps, Accessories), Technology (Battery Powered Pumps, Smart Pumps, Manual Pumps), Region, and Segment Forecasts, 2024-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Wearable Breast Pump Market Size, Share & Trends Analysis Report by Component (Wearable Pumps, Accessories), Technology (Battery Powered Pumps, Smart Pumps, Manual Pumps), Region, and Segment Forecasts, 2024-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global wearable breast pump market is estimated to reach USD 975.47 million by 2030, growing at a CAGR of 8.55%
    Favorable reimbursement policies, and increasing patient disposable income are further anticipated to propel the demand for wearable breast pumps.
  • Such instances are expected to increase the demand for wearable breast pumps, thereby propelling the market growth over the forecast period.
  • This will surge the need for wearable breast pumps for working women, thereby propelling the market growth in post COVID-19 time.

Momcozy Announces Exciting Partnership With Boots

Retrieved on: 
Wednesday, March 6, 2024

Boots, the UK's fastest-growing health and beauty retailer, has announced its partnership with Momcozy, the maker of the ultra-popular M5 Wearable Breast Pump as well as a wide range of maternity care products.

Key Points: 
  • Boots, the UK's fastest-growing health and beauty retailer, has announced its partnership with Momcozy, the maker of the ultra-popular M5 Wearable Breast Pump as well as a wide range of maternity care products.
  • As the industry-leading wearable breast pump manufacturer, Momcozy brings its highly sought-after pumping and nursing bras, lactation massager, and more to Boots' online marketplace, making quality maternity products more accessible throughout the UK.
  • View the full release here: https://www.businesswire.com/news/home/20240306523882/en/
    Momcozy Announces Exciting Partnership With Boots (Photo: Business Wire)
    Momcozy’s first shot to fame was in 2018 with their all-in-one M5 Wearable Breast Pump , which revolutionized pumping by creating a virtually pain-free and discreet way to express anytime, anywhere.
  • Endorsed by 3 million mothers in over 40 countries, Momcozy is a companion to women from pregnancy to early motherhood.

Butterfly Network to Participate at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference

Retrieved on: 
Wednesday, March 6, 2024

Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”) a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced that Joseph DeVivo, President, Chief Executive Officer and Chairman, and Heather Getz, Executive Vice President, Chief Financial and Operations Officer, will participate in a fireside chat and host one-on-one investor meetings at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference on March 13, 2024, at 8:40 am ET.

Key Points: 
  • Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”) a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced that Joseph DeVivo, President, Chief Executive Officer and Chairman, and Heather Getz, Executive Vice President, Chief Financial and Operations Officer, will participate in a fireside chat and host one-on-one investor meetings at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference on March 13, 2024, at 8:40 am ET.
  • The conference will be held virtually.
  • A webcast of the fireside chat will be available in the Events & Presentations section of the Butterfly investor website, and available for replay following the event until June 11, 2024.
  • To schedule a one-on-one meeting with Mr. DeVivo and Ms. Getz, please reach out to your Oppenheimer representative.

Igentify Launches New NIPT and Pharmacogenomics Offerings

Retrieved on: 
Tuesday, March 5, 2024

Igentify , a digital health company alleviating bottlenecks in the genetic testing process, announced the launch of its Non-Invasive Prenatal Testing (NIPT) and Pharmacogenomics (PGx) offerings via the Digital Genetic Assistant platform.

Key Points: 
  • Igentify , a digital health company alleviating bottlenecks in the genetic testing process, announced the launch of its Non-Invasive Prenatal Testing (NIPT) and Pharmacogenomics (PGx) offerings via the Digital Genetic Assistant platform.
  • This new roll-out comes in addition to their Expanded Carrier Screening (ECS) offering.
  • The NIPT workflow includes a patient web-app that facilitates all aspects of patient intake, including an ACOG-compliant consenting process using Igentify’s proprietary video technology to create highly personalized educational videos for each patient.
  • “We are thrilled to expand the accessibility of our platform with programs focused on non-invasive prenatal testing and pharmacogenomics,” said Elliott Greenspan, Chief Innovation Officer and Co-founder of Igentify.